Public Employees Retirement System of Ohio Sells 949 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• The Public Employees Retirement System of Ohio reduced its holdings in Regeneron Pharmaceuticals by 2.2%, now owning 42,540 shares valued at approximately $22.33 million.
• Regeneron Pharmaceuticals reported a quarterly EPS of $12.89, significantly exceeding estimates and achieving a 31.37% net margin for the quarter.
• Analysts have generally rated Regeneron Pharmaceuticals positively, with an average price target of $817.67 and a mix of buy and hold ratings.

Public Employees Retirement System of Ohio lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,540 shares of the biopharmaceutical company's stock after selling 949 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Regeneron Pharmaceuticals were worth $22,334,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Marietta Wealth Management LLC grew its stake in Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after acquiring an additional 2,501 shares in the last quarter. Sepio Capital LP boosted its holdings in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after purchasing an additional 842 shares during the period. Founders Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after purchasing an additional 538 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after buying an additional 955 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 3.7%

Shares of REGN opened at $555.51 on Friday. The stock has a market capitalization of $58.88 billion, a P/E ratio of 14.00, a PEG ratio of 1.84 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,070.00. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $569.36 and a two-hundred day simple moving average of $572.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.56 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analysts Set New Price Targets

Several equities analysts recently commented on REGN shares. Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. Morgan Stanley restated an "overweight" rating and issued a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Finally, Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.